Ampliphi Biosciences Corp Stock Nyse
Equities
APHB
US03211P2020
Biotechnology & Medical Research
Capitalization | 72M 68.94M 65.13M 57.43M 102M 6.24B 114M 775M 288M 2.6B 270M 264M 11.01B | P/E ratio 2024 * |
-2.09x | P/E ratio 2025 * | -1.17x |
---|---|---|---|---|---|
Enterprise value | 72M 68.94M 65.13M 57.43M 102M 6.24B 114M 775M 288M 2.6B 270M 264M 11.01B | EV / Sales 2024 * |
13.1x | EV / Sales 2025 * | 13.1x |
Free-Float |
29.75% | Yield 2024 * |
-
| Yield 2025 * | - |
Director | Title | Age | Since |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 69 | 2023-07-10 |
David House
DFI | Director of Finance/CFO | 41 | 2024-08-15 |
Peter Hubbard
COO | Chief Operating Officer | - | - |
Manager | Title | Age | Since |
---|---|---|---|
Joseph Patti
BRD | Director/Board Member | 61 | 2019-05-08 |
Todd Peterson
BRD | Director/Board Member | 67 | 2019-10-09 |
Director/Board Member | 65 | 2020-02-11 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+2.07% | -3.86% | +11.19% | +97.78% | 119B | ||
+1.57% | -6.62% | -28.31% | +5.62% | 72.16B | ||
-0.13% | -1.87% | +71.66% | +145.82% | 39.41B | ||
+9.73% | +2.37% | +35.55% | -28.18% | 29.44B | ||
+0.98% | -1.48% | +59.02% | +11.49% | 24.06B | ||
-1.34% | -2.05% | +7.04% | -31.55% | 22.32B | ||
+11.50% | +5.56% | +385.97% | +929.25% | 16.09B | ||
-1.17% | -2.61% | +195.75% | +237.06% | 14.07B | ||
+0.89% | +8.70% | -19.81% | -31.54% | 13.26B | ||
Average | +1.49% | -0.52% | +79.78% | +148.42% | 38.85B | |
Weighted average by Cap. | +0.56% | -2.74% | +38.43% | +98.34% |
2024 * | 2025 * | |
---|---|---|
Net sales | 5.5M 5.27M 4.97M 4.39M 7.82M 477M 8.73M 59.24M 21.98M 199M 20.61M 20.2M 841M | 5.5M 5.27M 4.97M 4.39M 7.82M 477M 8.73M 59.24M 21.98M 199M 20.61M 20.2M 841M |
Net income | -34.8M -33.32M -31.48M -27.75M -49.47M -3.02B -55.23M -375M -139M -1.26B -130M -128M -5.32B | -68.6M -65.68M -62.05M -54.71M -97.52M -5.95B -109M -739M -274M -2.48B -257M -252M -10.49B |
Net Debt | - | - |